BindingDB logo
myBDB logout
Compile Data Set for Download or QSAR

Found 1133 hits Enz. Inhib. hit(s) with Target = 'Neuropeptide Y receptor type 2'   
Target/Host
(Institution)
LigandTarget/Host
Links
Ligand
Links
Trg + Lig
Links
Ki
nM
ΔG°
kJ/mole
IC50
nM
Kd
nM
EC50/IC50
nM
koff
s-1
kon
M-1s-1
pHTemp
°C
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50240829
PNG
(CHEMBL3559801)
Show SMILES CC(C)(C)c1ccc(OC2CCCCC2O)cc1
Show InChI InChI=1S/C16H24O2/c1-16(2,3)12-8-10-13(11-9-12)18-15-7-5-4-6-14(15)17/h8-11,14-15,17H,4-7H2,1-3H3
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 0.0631n/an/an/an/a



Leipzig University

Curated by ChEMBL


Assay Description
Positive allosteric modulation of human C-terminal eYFP-fused human NY2 receptor expressed in African green monkey COS7 cells co-expressing delta6Gal...


J Med Chem 60: 7605-7612 (2017)


Article DOI: 10.1021/acs.jmedchem.7b00976
BindingDB Entry DOI: 10.7270/Q22B915R
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269165
PNG
(CHEMBL4090092)
Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](CCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C83H143N29O19/c1-45(114)65(77(129)104-53(28-17-35-97-82(92)93)67(119)102-55(30-31-63(85)116)70(122)100-51(26-15-33-95-80(88)89)68(120)105-56(66(87)118)37-47-19-8-5-9-20-47)110-79(131)83(3,4)111-75(127)54(25-14-32-84)101-74(126)60(41-64(86)117)109-72(124)58(39-49-23-12-7-13-24-49)106-71(123)57(38-48-21-10-6-11-22-48)107-73(125)59(40-50-42-94-44-98-50)108-69(121)52(27-16-34-96-81(90)91)103-76(128)62-29-18-36-112(62)78(130)61(43-113)99-46(2)115/h42,44-45,47-49,51-62,65,113-114H,5-41,43,84H2,1-4H3,(H2,85,116)(H2,86,117)(H2,87,118)(H,94,98)(H,99,115)(H,100,122)(H,101,126)(H,102,119)(H,103,128)(H,104,129)(H,105,120)(H,106,123)(H,107,125)(H,108,121)(H,109,124)(H,110,131)(H,111,127)(H4,88,89,95)(H4,90,91,96)(H4,92,93,97)/t45-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62-,65+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.0680n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269168
PNG
(CHEMBL4069205)
Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C84H145N31O19/c1-45(117)65(77(132)107-53(27-16-34-99-82(92)93)67(122)105-55(30-31-63(85)119)70(125)103-51(25-14-32-97-80(88)89)68(123)108-56(66(87)121)37-47-19-8-5-9-20-47)113-79(134)84(3,4)114-75(130)54(28-17-35-100-83(94)95)104-74(129)60(41-64(86)120)112-72(127)58(39-49-23-12-7-13-24-49)109-71(126)57(38-48-21-10-6-11-22-48)110-73(128)59(40-50-42-96-44-101-50)111-69(124)52(26-15-33-98-81(90)91)106-76(131)62-29-18-36-115(62)78(133)61(43-116)102-46(2)118/h42,44-45,47-49,51-62,65,116-117H,5-41,43H2,1-4H3,(H2,85,119)(H2,86,120)(H2,87,121)(H,96,101)(H,102,118)(H,103,125)(H,104,129)(H,105,122)(H,106,131)(H,107,132)(H,108,123)(H,109,126)(H,110,128)(H,111,124)(H,112,127)(H,113,134)(H,114,130)(H4,88,89,97)(H4,90,91,98)(H4,92,93,99)(H4,94,95,100)/t45-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62-,65+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem
PubMed
n/an/an/an/a 0.160n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269185
PNG
(CHEMBL4069788)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1S/C86H145N27O19/c1-47(2)40-59(78(128)112-86(5,6)82(132)111-68(48(3)115)80(130)104-56(28-18-36-99-85(94)95)70(120)102-57(30-31-66(87)117)73(123)101-54(26-16-34-97-83(90)91)71(121)105-58(69(89)119)41-50-20-10-7-11-21-50)106-77(127)63(45-67(88)118)110-76(126)61(43-52-24-14-9-15-25-52)109-74(124)60(42-51-22-12-8-13-23-51)108-75(125)62(44-53-32-37-96-38-33-53)107-72(122)55(27-17-35-98-84(92)93)103-79(129)65-29-19-39-113(65)81(131)64(46-114)100-49(4)116/h32-33,37-38,47-48,50-52,54-65,68,114-115H,7-31,34-36,39-46H2,1-6H3,(H2,87,117)(H2,88,118)(H2,89,119)(H,100,116)(H,101,123)(H,102,120)(H,103,129)(H,104,130)(H,105,121)(H,106,127)(H,107,122)(H,108,125)(H,109,124)(H,110,126)(H,111,132)(H,112,128)(H4,90,91,97)(H4,92,93,98)(H4,94,95,99)/t48-,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65-,68+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.190n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269163
PNG
(CHEMBL4094429)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C84H144N28O20/c1-44(2)33-57(76(128)111-84(5,6)80(132)110-66(45(3)114)78(130)103-54(27-18-32-97-83(92)93)68(120)101-55(28-29-64(85)117)71(123)100-52(25-16-30-95-81(88)89)69(121)104-56(67(87)119)34-47-19-10-7-11-20-47)105-75(127)61(39-65(86)118)109-73(125)59(36-49-23-14-9-15-24-49)106-72(124)58(35-48-21-12-8-13-22-48)107-74(126)60(37-50-40-94-43-98-50)108-70(122)53(26-17-31-96-82(90)91)102-77(129)63-38-51(116)41-112(63)79(131)62(42-113)99-46(4)115/h40,43-45,47-49,51-63,66,113-114,116H,7-39,41-42H2,1-6H3,(H2,85,117)(H2,86,118)(H2,87,119)(H,94,98)(H,99,115)(H,100,123)(H,101,120)(H,102,129)(H,103,130)(H,104,121)(H,105,127)(H,106,124)(H,107,126)(H,108,122)(H,109,125)(H,110,132)(H,111,128)(H4,88,89,95)(H4,90,91,96)(H4,92,93,97)/t45-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63-,66+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.200n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254345
PNG
(CHEMBL4075597)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(CC1CCCCC1)NC(=O)C(CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1C[C@H](O)CN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O
Show InChI InChI=1/C84H144N28O20/c1-44(2)33-57(76(128)111-84(5,6)80(132)110-66(45(3)114)78(130)103-54(27-18-32-97-83(92)93)68(120)101-55(28-29-64(85)117)71(123)100-52(25-16-30-95-81(88)89)69(121)104-56(67(87)119)34-47-19-10-7-11-20-47)105-75(127)61(39-65(86)118)109-73(125)59(36-49-23-14-9-15-24-49)106-72(124)58(35-48-21-12-8-13-22-48)107-74(126)60(37-50-40-94-43-98-50)108-70(122)53(26-17-31-96-82(90)91)102-77(129)63-38-51(116)41-112(63)79(131)62(42-113)99-46(4)115/h40,43-45,47-49,51-63,66,113-114,116H,7-39,41-42H2,1-6H3,(H2,85,117)(H2,86,118)(H2,87,119)(H,94,98)(H,99,115)(H,100,123)(H,101,120)(H,102,129)(H,103,130)(H,104,121)(H,105,127)(H,106,124)(H,107,126)(H,108,122)(H,109,125)(H,110,132)(H,111,128)(H4,88,89,95)(H4,90,91,96)(H4,92,93,97)/t45-,51+,52+,53+,54+,55+,56?,57+,58?,59?,60+,61+,62+,63-,66+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
MMDB
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.200n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269166
PNG
(CHEMBL4063306)
Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C84H145N29O19/c1-46(115)66(78(130)105-54(29-18-36-98-83(93)94)68(120)103-56(31-32-64(86)117)71(123)101-52(27-16-34-96-81(89)90)69(121)106-57(67(88)119)38-48-20-8-5-9-21-48)111-80(132)84(3,4)112-76(128)55(26-14-15-33-85)102-75(127)61(42-65(87)118)110-73(125)59(40-50-24-12-7-13-25-50)107-72(124)58(39-49-22-10-6-11-23-49)108-74(126)60(41-51-43-95-45-99-51)109-70(122)53(28-17-35-97-82(91)92)104-77(129)63-30-19-37-113(63)79(131)62(44-114)100-47(2)116/h43,45-46,48-50,52-63,66,114-115H,5-42,44,85H2,1-4H3,(H2,86,117)(H2,87,118)(H2,88,119)(H,95,99)(H,100,116)(H,101,123)(H,102,127)(H,103,120)(H,104,129)(H,105,130)(H,106,121)(H,107,124)(H,108,126)(H,109,122)(H,110,125)(H,111,132)(H,112,128)(H4,89,90,96)(H4,91,92,97)(H4,93,94,98)/t46-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63-,66+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.200n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269184
PNG
(CHEMBL4064778)
Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)C(C)(C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1S/C81H138N28O19/c1-44(111)62(73(125)101-51(26-17-35-95-79(90)91)64(116)99-53(28-29-60(83)113)67(119)97-49(24-15-33-93-77(86)87)65(117)102-54(63(85)115)39-46-19-9-7-10-20-46)106-76(128)81(5,6)107-70(122)52(23-13-14-32-82)98-69(121)57(42-61(84)114)105-75(127)80(3,4)108-71(123)56(40-47-21-11-8-12-22-47)104-68(120)55(41-48-30-36-92-37-31-48)103-66(118)50(25-16-34-94-78(88)89)100-72(124)59-27-18-38-109(59)74(126)58(43-110)96-45(2)112/h30-31,36-37,44,46-47,49-59,62,110-111H,7-29,32-35,38-43,82H2,1-6H3,(H2,83,113)(H2,84,114)(H2,85,115)(H,96,112)(H,97,119)(H,98,121)(H,99,116)(H,100,124)(H,101,125)(H,102,117)(H,103,118)(H,104,120)(H,105,127)(H,106,128)(H,107,122)(H,108,123)(H4,86,87,93)(H4,88,89,94)(H4,90,91,95)/t44-,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59-,62+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.200n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269142
PNG
(CHEMBL4065281)
Show SMILES CCCC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C84H144N28O19/c1-6-7-27-55(76(127)111-84(4,5)80(131)110-66(46(2)114)78(129)104-54(30-19-36-97-83(92)93)68(119)102-56(32-33-64(85)116)71(122)100-52(28-17-34-95-81(88)89)69(120)105-57(67(87)118)38-48-21-11-8-12-22-48)101-75(126)61(42-65(86)117)109-73(124)59(40-50-25-15-10-16-26-50)106-72(123)58(39-49-23-13-9-14-24-49)107-74(125)60(41-51-43-94-45-98-51)108-70(121)53(29-18-35-96-82(90)91)103-77(128)63-31-20-37-112(63)79(130)62(44-113)99-47(3)115/h43,45-46,48-50,52-63,66,113-114H,6-42,44H2,1-5H3,(H2,85,116)(H2,86,117)(H2,87,118)(H,94,98)(H,99,115)(H,100,122)(H,101,126)(H,102,119)(H,103,128)(H,104,129)(H,105,120)(H,106,123)(H,107,125)(H,108,121)(H,109,124)(H,110,131)(H,111,127)(H4,88,89,95)(H4,90,91,96)(H4,92,93,97)/t46-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63-,66+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem
PubMed
n/an/an/an/a 0.210n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50197025
PNG
(CHEMBL439904 | PYY(3-36))
Show SMILES CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1S/C180H279N53O54/c1-17-91(12)141(185)171(282)214-114(27-18-19-61-181)175(286)232-67-25-33-130(232)169(280)211-111(53-58-137(247)248)147(258)204-94(15)174(285)231-66-24-32-129(231)168(279)200-82-135(244)205-109(52-57-136(245)246)152(263)226-126(80-140(253)254)157(268)203-93(14)146(257)228-128(84-235)176(287)233-68-26-34-131(233)170(281)212-113(55-60-139(251)252)154(265)210-112(54-59-138(249)250)155(266)216-117(70-87(4)5)159(270)224-124(78-133(183)242)164(275)208-106(29-21-63-197-178(189)190)150(261)220-121(75-98-39-47-103(239)48-40-98)162(273)221-120(74-97-37-45-102(238)46-38-97)156(267)202-92(13)145(256)227-127(83-234)167(278)219-116(69-86(2)3)158(269)207-107(30-22-64-198-179(191)192)151(262)223-123(77-100-81-195-85-201-100)163(274)222-122(76-99-41-49-104(240)50-42-99)161(272)217-118(71-88(6)7)160(271)225-125(79-134(184)243)165(276)218-119(72-89(8)9)166(277)229-142(90(10)11)172(283)230-143(95(16)236)173(284)213-108(31-23-65-199-180(193)194)148(259)209-110(51-56-132(182)241)153(264)206-105(28-20-62-196-177(187)188)149(260)215-115(144(186)255)73-96-35-43-101(237)44-36-96/h35-50,81,85-95,105-131,141-143,234-240H,17-34,51-80,82-84,181,185H2,1-16H3,(H2,182,241)(H2,183,242)(H2,184,243)(H2,186,255)(H,195,201)(H,200,279)(H,202,267)(H,203,268)(H,204,258)(H,205,244)(H,206,264)(H,207,269)(H,208,275)(H,209,259)(H,210,265)(H,211,280)(H,212,281)(H,213,284)(H,214,282)(H,215,260)(H,216,266)(H,217,272)(H,218,276)(H,219,278)(H,220,261)(H,221,273)(H,222,274)(H,223,262)(H,224,270)(H,225,271)(H,226,263)(H,227,256)(H,228,257)(H,229,277)(H,230,283)(H,245,246)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H4,187,188,196)(H4,189,190,197)(H4,191,192,198)(H4,193,194,199)/t91-,92-,93-,94-,95+,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,141-,142-,143-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.280n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254346
PNG
(CHEMBL4069932)
Show SMILES CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C180H279N53O54/c1-17-91(12)141(185)171(282)214-114(27-18-19-61-181)175(286)232-67-25-33-130(232)169(280)211-111(53-58-137(247)248)147(258)204-94(15)174(285)231-66-24-32-129(231)168(279)200-82-135(244)205-109(52-57-136(245)246)152(263)226-126(80-140(253)254)157(268)203-93(14)146(257)228-128(84-235)176(287)233-68-26-34-131(233)170(281)212-113(55-60-139(251)252)154(265)210-112(54-59-138(249)250)155(266)216-117(70-87(4)5)159(270)224-124(78-133(183)242)164(275)208-106(29-21-63-197-178(189)190)150(261)220-121(75-98-39-47-103(239)48-40-98)162(273)221-120(74-97-37-45-102(238)46-38-97)156(267)202-92(13)145(256)227-127(83-234)167(278)219-116(69-86(2)3)158(269)207-107(30-22-64-198-179(191)192)151(262)223-123(77-100-81-195-85-201-100)163(274)222-122(76-99-41-49-104(240)50-42-99)161(272)217-118(71-88(6)7)160(271)225-125(79-134(184)243)165(276)218-119(72-89(8)9)166(277)229-142(90(10)11)172(283)230-143(95(16)236)173(284)213-108(31-23-65-199-180(193)194)148(259)209-110(51-56-132(182)241)153(264)206-105(28-20-62-196-177(187)188)149(260)215-115(144(186)255)73-96-35-43-101(237)44-36-96/h35-50,81,85-95,105-131,141-143,234-240H,17-34,51-80,82-84,181,185H2,1-16H3,(H2,182,241)(H2,183,242)(H2,184,243)(H2,186,255)(H,195,201)(H,200,279)(H,202,267)(H,203,268)(H,204,258)(H,205,244)(H,206,264)(H,207,269)(H,208,275)(H,209,259)(H,210,265)(H,211,280)(H,212,281)(H,213,284)(H,214,282)(H,215,260)(H,216,266)(H,217,272)(H,218,276)(H,219,278)(H,220,261)(H,221,273)(H,222,274)(H,223,262)(H,224,270)(H,225,271)(H,226,263)(H,227,256)(H,228,257)(H,229,277)(H,230,283)(H,245,246)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H4,187,188,196)(H4,189,190,197)(H4,191,192,198)(H4,193,194,199)/t91-,92-,93-,94-,95-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,141-,142-,143-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.280n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50197025
PNG
(CHEMBL439904 | PYY(3-36))
Show SMILES CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1S/C180H279N53O54/c1-17-91(12)141(185)171(282)214-114(27-18-19-61-181)175(286)232-67-25-33-130(232)169(280)211-111(53-58-137(247)248)147(258)204-94(15)174(285)231-66-24-32-129(231)168(279)200-82-135(244)205-109(52-57-136(245)246)152(263)226-126(80-140(253)254)157(268)203-93(14)146(257)228-128(84-235)176(287)233-68-26-34-131(233)170(281)212-113(55-60-139(251)252)154(265)210-112(54-59-138(249)250)155(266)216-117(70-87(4)5)159(270)224-124(78-133(183)242)164(275)208-106(29-21-63-197-178(189)190)150(261)220-121(75-98-39-47-103(239)48-40-98)162(273)221-120(74-97-37-45-102(238)46-38-97)156(267)202-92(13)145(256)227-127(83-234)167(278)219-116(69-86(2)3)158(269)207-107(30-22-64-198-179(191)192)151(262)223-123(77-100-81-195-85-201-100)163(274)222-122(76-99-41-49-104(240)50-42-99)161(272)217-118(71-88(6)7)160(271)225-125(79-134(184)243)165(276)218-119(72-89(8)9)166(277)229-142(90(10)11)172(283)230-143(95(16)236)173(284)213-108(31-23-65-199-180(193)194)148(259)209-110(51-56-132(182)241)153(264)206-105(28-20-62-196-177(187)188)149(260)215-115(144(186)255)73-96-35-43-101(237)44-36-96/h35-50,81,85-95,105-131,141-143,234-240H,17-34,51-80,82-84,181,185H2,1-16H3,(H2,182,241)(H2,183,242)(H2,184,243)(H2,186,255)(H,195,201)(H,200,279)(H,202,267)(H,203,268)(H,204,258)(H,205,244)(H,206,264)(H,207,269)(H,208,275)(H,209,259)(H,210,265)(H,211,280)(H,212,281)(H,213,284)(H,214,282)(H,215,260)(H,216,266)(H,217,272)(H,218,276)(H,219,278)(H,220,261)(H,221,273)(H,222,274)(H,223,262)(H,224,270)(H,225,271)(H,226,263)(H,227,256)(H,228,257)(H,229,277)(H,230,283)(H,245,246)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H4,187,188,196)(H4,189,190,197)(H4,191,192,198)(H4,193,194,199)/t91-,92-,93-,94-,95+,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,141-,142-,143-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 0.300n/an/an/an/a



Bayer Pharmaceuticals Corporation

Curated by ChEMBL


Assay Description
Agonist activity at human NPY2 receptor expressed in human KAN-TS cells by [35S]GTPgammaS incorporation assay


Bioorg Med Chem Lett 17: 538-41 (2007)


Article DOI: 10.1016/j.bmcl.2006.10.007
BindingDB Entry DOI: 10.7270/Q2959H6F
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50444592
PNG
(CHEMBL3099721)
Show SMILES CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)O[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C177H272N52O55/c1-16-88(10)138(182)167(277)211-111(26-17-18-60-178)171(281)228-66-24-32-126(228)165(275)208-108(52-57-134(243)244)145(255)202-92(14)170(280)227-65-23-31-125(227)164(274)197-80-132(240)203-106(51-56-133(241)242)149(259)222-122(78-137(249)250)155(265)200-90(12)143(253)224-124(82-231)172(282)229-67-25-33-127(229)166(276)209-110(54-59-136(247)248)150(260)207-109(53-58-135(245)246)152(262)213-114(69-85(4)5)157(267)221-121(77-131(181)239)162(272)205-103(27-19-61-193-174(184)185)147(257)216-117(72-95-36-44-100(234)45-37-95)160(270)217-116(71-94-34-42-99(233)43-35-94)153(263)199-89(11)142(252)223-123(81-230)163(273)215-113(68-84(2)3)156(266)204-104(28-20-62-194-175(186)187)148(258)219-119(75-98-79-192-83-198-98)161(271)218-118(73-96-38-46-101(235)47-39-96)159(269)214-115(70-86(6)7)158(268)220-120(76-130(180)238)154(264)201-91(13)144(254)225-139(87(8)9)168(278)226-140(93(15)232)169(279)210-105(29-21-63-195-176(188)189)146(256)206-107(50-55-129(179)237)151(261)212-112(30-22-64-196-177(190)191)173(283)284-128(141(183)251)74-97-40-48-102(236)49-41-97/h34-49,79,83-93,103-128,138-140,230-236H,16-33,50-78,80-82,178,182H2,1-15H3,(H2,179,237)(H2,180,238)(H2,181,239)(H2,183,251)(H,192,198)(H,197,274)(H,199,263)(H,200,265)(H,201,264)(H,202,255)(H,203,240)(H,204,266)(H,205,272)(H,206,256)(H,207,260)(H,208,275)(H,209,276)(H,210,279)(H,211,277)(H,212,261)(H,213,262)(H,214,269)(H,215,273)(H,216,257)(H,217,270)(H,218,271)(H,219,258)(H,220,268)(H,221,267)(H,222,259)(H,223,252)(H,224,253)(H,225,254)(H,226,278)(H,241,242)(H,243,244)(H,245,246)(H,247,248)(H,249,250)(H4,184,185,193)(H4,186,187,194)(H4,188,189,195)(H4,190,191,196)/t88-,89-,90-,91-,92-,93+,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,138-,139-,140-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/an/an/a 0.300n/an/an/an/a



University of Copenhagen

Curated by ChEMBL


Assay Description
Agonist activity at human NPYY2 receptor expressed in HEK293 cells assessed as decrease in isoproterenol-induced cAMP level measured every 30 secs fo...


ACS Med Chem Lett 4: 1228-32 (2013)


Article DOI: 10.1021/ml400335g
BindingDB Entry DOI: 10.7270/Q28S4RD1
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269169
PNG
(CHEMBL4090786)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1S/C81H142N26O20/c1-43(2)36-54(73(123)106-81(5,6)77(127)105-63(44(3)110)75(125)98-51(28-18-34-93-80(89)90)65(115)96-52(30-31-61(82)112)68(118)95-49(26-16-32-91-78(85)86)66(116)99-53(64(84)114)37-46-20-10-7-11-21-46)100-71(121)57(40-62(83)113)103-70(120)55(38-47-22-12-8-13-23-47)101-69(119)56(39-48-24-14-9-15-25-48)102-72(122)58(41-108)104-67(117)50(27-17-33-92-79(87)88)97-74(124)60-29-19-35-107(60)76(126)59(42-109)94-45(4)111/h43-44,46-60,63,108-110H,7-42H2,1-6H3,(H2,82,112)(H2,83,113)(H2,84,114)(H,94,111)(H,95,118)(H,96,115)(H,97,124)(H,98,125)(H,99,116)(H,100,121)(H,101,119)(H,102,122)(H,103,120)(H,104,117)(H,105,127)(H,106,123)(H4,85,86,91)(H4,87,88,92)(H4,89,90,93)/t44-,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60-,63+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem
PubMed
n/an/an/an/a 0.330n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50089442
PNG
(CHEMBL3578012)
Show SMILES CC(C)C[C@H](NC(=O)C(CN)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C84H137N29O20/c1-41(2)30-57(109-80(132)64(38-85)100-46(10)115)73(125)102-53(15-12-28-97-83(91)92)71(123)111-62(36-49-39-95-40-99-49)77(129)110-61(35-48-19-23-51(117)24-20-48)76(128)106-59(32-43(5)6)75(127)112-63(37-66(87)119)78(130)107-58(31-42(3)4)74(126)108-60(33-44(7)8)79(131)113-67(45(9)114)81(133)104-54(16-13-29-98-84(93)94)69(121)103-55(25-26-65(86)118)72(124)101-52(14-11-27-96-82(89)90)70(122)105-56(68(88)120)34-47-17-21-50(116)22-18-47/h17-24,39-45,52-64,67,114,116-117H,11-16,25-38,85H2,1-10H3,(H2,86,118)(H2,87,119)(H2,88,120)(H,95,99)(H,100,115)(H,101,124)(H,102,125)(H,103,121)(H,104,133)(H,105,122)(H,106,128)(H,107,130)(H,108,126)(H,109,132)(H,110,129)(H,111,123)(H,112,127)(H,113,131)(H4,89,90,96)(H4,91,92,97)(H4,93,94,98)/t45-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64?,67+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 0.398n/an/an/an/a



Universit£t Leipzig

Curated by ChEMBL


Assay Description
Agonist activity at human neuropeptide Y Y2 receptor expressed in COS-7 cells cotransfected with chimeric Gi/q protein assessed as inositol phosphate...


J Med Chem 58: 4180-93 (2015)


Article DOI: 10.1021/jm501702q
BindingDB Entry DOI: 10.7270/Q2P84DNK
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50089442
PNG
(CHEMBL3578012)
Show SMILES CC(C)C[C@H](NC(=O)C(CN)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C84H137N29O20/c1-41(2)30-57(109-80(132)64(38-85)100-46(10)115)73(125)102-53(15-12-28-97-83(91)92)71(123)111-62(36-49-39-95-40-99-49)77(129)110-61(35-48-19-23-51(117)24-20-48)76(128)106-59(32-43(5)6)75(127)112-63(37-66(87)119)78(130)107-58(31-42(3)4)74(126)108-60(33-44(7)8)79(131)113-67(45(9)114)81(133)104-54(16-13-29-98-84(93)94)69(121)103-55(25-26-65(86)118)72(124)101-52(14-11-27-96-82(89)90)70(122)105-56(68(88)120)34-47-17-21-50(116)22-18-47/h17-24,39-45,52-64,67,114,116-117H,11-16,25-38,85H2,1-10H3,(H2,86,118)(H2,87,119)(H2,88,120)(H,95,99)(H,100,115)(H,101,124)(H,102,125)(H,103,121)(H,104,133)(H,105,122)(H,106,128)(H,107,130)(H,108,126)(H,109,132)(H,110,129)(H,111,123)(H,112,127)(H,113,131)(H4,89,90,96)(H4,91,92,97)(H4,93,94,98)/t45-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64?,67+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 0.400n/an/an/an/a



Universit£t Leipzig

Curated by ChEMBL


Assay Description
Agonist activity at human neuropeptide Y Y2 receptor expressed in COS-7 cells cotransfected with chimeric Gi/q protein assessed as inositol phosphate...


J Med Chem 58: 4180-93 (2015)


Article DOI: 10.1021/jm501702q
BindingDB Entry DOI: 10.7270/Q2P84DNK
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269167
PNG
(CHEMBL4085697)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@](C)(CC(C)C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C82H142N28O19/c1-43(2)34-55(71(123)108-81(7,8)76(128)107-63(45(5)112)74(126)101-52(26-18-32-95-80(90)91)65(117)99-53(28-29-61(83)114)68(120)98-50(24-16-30-93-78(86)87)66(118)102-54(64(85)116)35-47-20-12-10-13-21-47)103-70(122)58(38-62(84)115)106-77(129)82(9,39-44(3)4)109-72(124)56(36-48-22-14-11-15-23-48)104-69(121)57(37-49-40-92-42-96-49)105-67(119)51(25-17-31-94-79(88)89)100-73(125)60-27-19-33-110(60)75(127)59(41-111)97-46(6)113/h40,42-45,47-48,50-60,63,111-112H,10-39,41H2,1-9H3,(H2,83,114)(H2,84,115)(H2,85,116)(H,92,96)(H,97,113)(H,98,120)(H,99,117)(H,100,125)(H,101,126)(H,102,118)(H,103,122)(H,104,121)(H,105,119)(H,106,129)(H,107,128)(H,108,123)(H,109,124)(H4,86,87,93)(H4,88,89,94)(H4,90,91,95)/t45-,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60-,63+,82+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.410n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269170
PNG
(CHEMBL4097195)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1S/C83H145N27O20/c1-44(2)38-56(75(126)109-83(5,6)79(130)108-65(45(3)112)77(128)102-52(28-18-36-96-82(92)93)68(119)99-53(30-32-62(84)114)70(121)98-50(26-16-34-94-80(88)89)69(120)103-55(66(87)117)39-47-20-10-7-11-21-47)104-74(125)59(42-64(86)116)107-73(124)58(41-49-24-14-9-15-25-49)106-72(123)57(40-48-22-12-8-13-23-48)105-71(122)54(31-33-63(85)115)100-67(118)51(27-17-35-95-81(90)91)101-76(127)61-29-19-37-110(61)78(129)60(43-111)97-46(4)113/h44-45,47-61,65,111-112H,7-43H2,1-6H3,(H2,84,114)(H2,85,115)(H2,86,116)(H2,87,117)(H,97,113)(H,98,121)(H,99,119)(H,100,118)(H,101,127)(H,102,128)(H,103,120)(H,104,125)(H,105,122)(H,106,123)(H,107,124)(H,108,130)(H,109,126)(H4,88,89,94)(H4,90,91,95)(H4,92,93,96)/t45-,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61-,65+/m1/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.420n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269143
PNG
(CHEMBL4090126)
Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C86H141N29O19/c1-47(117)68(80(132)106-56(26-16-34-100-85(94)95)70(122)104-57(28-29-66(87)119)73(125)103-54(24-14-32-98-83(90)91)71(123)107-58(69(89)121)38-49-18-8-5-9-19-49)113-82(134)86(3,4)114-78(130)61(41-52-30-35-96-36-31-52)110-77(129)63(43-67(88)120)112-75(127)60(40-51-22-12-7-13-23-51)108-74(126)59(39-50-20-10-6-11-21-50)109-76(128)62(42-53-44-97-46-101-53)111-72(124)55(25-15-33-99-84(92)93)105-79(131)65-27-17-37-115(65)81(133)64(45-116)102-48(2)118/h30-31,35-36,44,46-47,49-51,54-65,68,116-117H,5-29,32-34,37-43,45H2,1-4H3,(H2,87,119)(H2,88,120)(H2,89,121)(H,97,101)(H,102,118)(H,103,125)(H,104,122)(H,105,131)(H,106,132)(H,107,123)(H,108,126)(H,109,128)(H,110,129)(H,111,124)(H,112,127)(H,113,134)(H,114,130)(H4,90,91,98)(H4,92,93,99)(H4,94,95,100)/t47-,54+,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65-,68+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.480n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50089433
PNG
(CHEMBL3578011)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C87H143N29O20/c1-44(2)34-61(109-72(124)55(103-49(10)118)16-11-12-30-88)77(129)105-57(18-14-32-100-86(94)95)75(127)114-66(40-52-42-98-43-102-52)81(133)113-65(39-51-22-26-54(120)27-23-51)80(132)110-63(36-46(5)6)79(131)115-67(41-69(90)122)82(134)111-62(35-45(3)4)78(130)112-64(37-47(7)8)83(135)116-70(48(9)117)84(136)107-58(19-15-33-101-87(96)97)73(125)106-59(28-29-68(89)121)76(128)104-56(17-13-31-99-85(92)93)74(126)108-60(71(91)123)38-50-20-24-53(119)25-21-50/h20-27,42-48,55-67,70,117,119-120H,11-19,28-41,88H2,1-10H3,(H2,89,121)(H2,90,122)(H2,91,123)(H,98,102)(H,103,118)(H,104,128)(H,105,129)(H,106,125)(H,107,136)(H,108,126)(H,109,124)(H,110,132)(H,111,134)(H,112,130)(H,113,133)(H,114,127)(H,115,131)(H,116,135)(H4,92,93,99)(H4,94,95,100)(H4,96,97,101)/t48-,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,70+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 0.5n/an/an/an/a



Universit£t Leipzig

Curated by ChEMBL


Assay Description
Agonist activity at human neuropeptide Y Y2 receptor expressed in COS-7 cells cotransfected with chimeric Gi/q protein assessed as inositol phosphate...


J Med Chem 58: 4180-93 (2015)


Article DOI: 10.1021/jm501702q
BindingDB Entry DOI: 10.7270/Q2P84DNK
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50089433
PNG
(CHEMBL3578011)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CCCCN)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C87H143N29O20/c1-44(2)34-61(109-72(124)55(103-49(10)118)16-11-12-30-88)77(129)105-57(18-14-32-100-86(94)95)75(127)114-66(40-52-42-98-43-102-52)81(133)113-65(39-51-22-26-54(120)27-23-51)80(132)110-63(36-46(5)6)79(131)115-67(41-69(90)122)82(134)111-62(35-45(3)4)78(130)112-64(37-47(7)8)83(135)116-70(48(9)117)84(136)107-58(19-15-33-101-87(96)97)73(125)106-59(28-29-68(89)121)76(128)104-56(17-13-31-99-85(92)93)74(126)108-60(71(91)123)38-50-20-24-53(119)25-21-50/h20-27,42-48,55-67,70,117,119-120H,11-19,28-41,88H2,1-10H3,(H2,89,121)(H2,90,122)(H2,91,123)(H,98,102)(H,103,118)(H,104,128)(H,105,129)(H,106,125)(H,107,136)(H,108,126)(H,109,124)(H,110,132)(H,111,134)(H,112,130)(H,113,133)(H,114,127)(H,115,131)(H,116,135)(H4,92,93,99)(H4,94,95,100)(H4,96,97,101)/t48-,55+,56+,57+,58+,59+,60+,61+,62+,63+,64+,65+,66+,67+,70+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 0.501n/an/an/an/a



Universit£t Leipzig

Curated by ChEMBL


Assay Description
Agonist activity at human neuropeptide Y Y2 receptor expressed in COS-7 cells cotransfected with chimeric Gi/q protein assessed as inositol phosphate...


J Med Chem 58: 4180-93 (2015)


Article DOI: 10.1021/jm501702q
BindingDB Entry DOI: 10.7270/Q2P84DNK
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254336
PNG
(CHEMBL4092494)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(CC1CCCCC1)NC(=O)C(CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)C(C)(C)NC(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O
Show InChI InChI=1/C83H144N28O19/c1-44(2)35-56(74(126)110-83(7,8)78(130)109-64(45(3)113)76(128)101-52(28-19-33-95-80(89)90)66(118)100-54(30-31-62(84)115)69(121)99-51(27-18-32-94-79(87)88)67(119)102-55(65(86)117)36-47-21-12-9-13-22-47)103-73(125)60(40-63(85)116)107-71(123)58(38-49-25-16-11-17-26-49)104-70(122)57(37-48-23-14-10-15-24-48)105-72(124)59(39-50-41-93-43-97-50)106-68(120)53(29-20-34-96-81(91)92)108-77(129)82(5,6)111-75(127)61(42-112)98-46(4)114/h41,43-45,47-49,51-61,64,112-113H,9-40,42H2,1-8H3,(H2,84,115)(H2,85,116)(H2,86,117)(H,93,97)(H,98,114)(H,99,121)(H,100,118)(H,101,128)(H,102,119)(H,103,125)(H,104,122)(H,105,124)(H,106,120)(H,107,123)(H,108,129)(H,109,130)(H,110,126)(H,111,127)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t45-,51+,52+,53+,54+,55?,56+,57?,58?,59+,60+,61+,64+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.550n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254294
PNG
(CHEMBL4099784)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(CC1CCCCC1)NC(=O)C(CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](C)N(C)C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O
Show InChI InChI=1/C83H144N28O19/c1-44(2)35-57(76(127)110-83(6,7)79(130)109-65(46(4)113)77(128)102-54(29-20-34-96-82(91)92)68(119)101-55(30-31-63(84)115)71(122)100-53(28-19-33-95-81(89)90)69(120)103-56(66(86)117)36-48-21-12-9-13-22-48)104-75(126)61(40-64(85)116)108-73(124)59(38-50-25-16-11-17-26-50)105-72(123)58(37-49-23-14-10-15-24-49)106-74(125)60(39-51-41-93-43-97-51)107-70(121)52(27-18-32-94-80(87)88)99-67(118)45(3)111(8)78(129)62(42-112)98-47(5)114/h41,43-46,48-50,52-62,65,112-113H,9-40,42H2,1-8H3,(H2,84,115)(H2,85,116)(H2,86,117)(H,93,97)(H,98,114)(H,99,118)(H,100,122)(H,101,119)(H,102,128)(H,103,120)(H,104,126)(H,105,123)(H,106,125)(H,107,121)(H,108,124)(H,109,130)(H,110,127)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t45-,46-,52+,53+,54+,55+,56?,57+,58?,59?,60+,61+,62+,65+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
MMDB
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.590n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269150
PNG
(CHEMBL4098787)
Show SMILES C[C@@H](O)[C@H](NC(=O)C(C)(C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C81H138N28O20/c1-43(112)63(75(127)100-51(26-16-32-94-80(89)90)65(117)98-52(28-29-61(82)114)68(120)97-49(24-14-30-92-78(85)86)66(118)101-53(64(84)116)34-45-18-8-5-9-19-45)107-77(129)81(3,4)108-73(125)58(40-110)106-72(124)57(38-62(83)115)105-70(122)55(36-47-22-12-7-13-23-47)102-69(121)54(35-46-20-10-6-11-21-46)103-71(123)56(37-48-39-91-42-95-48)104-67(119)50(25-15-31-93-79(87)88)99-74(126)60-27-17-33-109(60)76(128)59(41-111)96-44(2)113/h39,42-43,45-47,49-60,63,110-112H,5-38,40-41H2,1-4H3,(H2,82,114)(H2,83,115)(H2,84,116)(H,91,95)(H,96,113)(H,97,120)(H,98,117)(H,99,126)(H,100,127)(H,101,118)(H,102,121)(H,103,123)(H,104,119)(H,105,122)(H,106,124)(H,107,129)(H,108,125)(H4,85,86,92)(H4,87,88,93)(H4,89,90,94)/t43-,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60-,63+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Patents


Similars

PubMed
n/an/an/an/a 0.600n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50089441
PNG
(CHEMBL3578010)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C136H210N42O38/c1-65(2)50-90(168-128(212)100(63-180)175-110(194)70(11)156-118(202)94(55-73-25-33-78(183)34-26-73)170-123(207)95(56-74-27-35-79(184)36-28-74)169-113(197)83(19-14-46-152-134(144)145)159-125(209)98(59-103(139)187)173-120(204)91(51-66(3)4)165-117(201)87(40-43-105(189)190)161-116(200)88(41-44-106(191)192)162-129(213)101-22-17-49-178(101)132(216)81(137)62-179)119(203)158-84(20-15-47-153-135(146)147)114(198)172-97(58-76-61-150-64-155-76)124(208)171-96(57-75-29-37-80(185)38-30-75)122(206)166-92(52-67(5)6)121(205)174-99(60-104(140)188)126(210)167-93(53-68(7)8)127(211)176-107(69(9)10)130(214)177-108(71(12)181)131(215)163-85(21-16-48-154-136(148)149)111(195)160-86(39-42-102(138)186)115(199)157-82(18-13-45-151-133(142)143)112(196)164-89(109(141)193)54-72-23-31-77(182)32-24-72/h23-38,61,64-71,81-101,107-108,179-185H,13-22,39-60,62-63,137H2,1-12H3,(H2,138,186)(H2,139,187)(H2,140,188)(H2,141,193)(H,150,155)(H,156,202)(H,157,199)(H,158,203)(H,159,209)(H,160,195)(H,161,200)(H,162,213)(H,163,215)(H,164,196)(H,165,201)(H,166,206)(H,167,210)(H,168,212)(H,169,197)(H,170,207)(H,171,208)(H,172,198)(H,173,204)(H,174,205)(H,175,194)(H,176,211)(H,177,214)(H,189,190)(H,191,192)(H4,142,143,151)(H4,144,145,152)(H4,146,147,153)(H4,148,149,154)/t70-,71+,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,107-,108-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 0.600n/an/an/an/a



Universit£t Leipzig

Curated by ChEMBL


Assay Description
Agonist activity at human neuropeptide Y Y2 receptor expressed in COS-7 cells cotransfected with chimeric Gi/q protein assessed as inositol phosphate...


J Med Chem 58: 4180-93 (2015)


Article DOI: 10.1021/jm501702q
BindingDB Entry DOI: 10.7270/Q2P84DNK
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254344
PNG
(CHEMBL4090700)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(CC1CCCCC1)NC(=O)C(CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O
Show InChI InChI=1/C84H144N28O19/c1-45(2)36-57(76(127)111-84(5,6)80(131)110-66(46(3)114)78(129)103-54(28-18-34-97-83(92)93)68(119)101-55(30-31-64(85)116)71(122)100-52(26-16-32-95-81(88)89)69(120)104-56(67(87)118)37-48-20-10-7-11-21-48)105-75(126)61(41-65(86)117)109-73(124)59(39-50-24-14-9-15-25-50)106-72(123)58(38-49-22-12-8-13-23-49)107-74(125)60(40-51-42-94-44-98-51)108-70(121)53(27-17-33-96-82(90)91)102-77(128)63-29-19-35-112(63)79(130)62(43-113)99-47(4)115/h42,44-46,48-50,52-63,66,113-114H,7-41,43H2,1-6H3,(H2,85,116)(H2,86,117)(H2,87,118)(H,94,98)(H,99,115)(H,100,122)(H,101,119)(H,102,128)(H,103,129)(H,104,120)(H,105,126)(H,106,123)(H,107,125)(H,108,121)(H,109,124)(H,110,131)(H,111,127)(H4,88,89,95)(H4,90,91,96)(H4,92,93,97)/t46-,52+,53+,54+,55+,56?,57+,58?,59?,60+,61+,62+,63-,66+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
MMDB
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.610n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269151
PNG
(CHEMBL4073010)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C84H144N28O19/c1-45(2)36-57(76(127)111-84(5,6)80(131)110-66(46(3)114)78(129)103-54(28-18-34-97-83(92)93)68(119)101-55(30-31-64(85)116)71(122)100-52(26-16-32-95-81(88)89)69(120)104-56(67(87)118)37-48-20-10-7-11-21-48)105-75(126)61(41-65(86)117)109-73(124)59(39-50-24-14-9-15-25-50)106-72(123)58(38-49-22-12-8-13-23-49)107-74(125)60(40-51-42-94-44-98-51)108-70(121)53(27-17-33-96-82(90)91)102-77(128)63-29-19-35-112(63)79(130)62(43-113)99-47(4)115/h42,44-46,48-50,52-63,66,113-114H,7-41,43H2,1-6H3,(H2,85,116)(H2,86,117)(H2,87,118)(H,94,98)(H,99,115)(H,100,122)(H,101,119)(H,102,128)(H,103,129)(H,104,120)(H,105,126)(H,106,123)(H,107,125)(H,108,121)(H,109,124)(H,110,131)(H,111,127)(H4,88,89,95)(H4,90,91,96)(H4,92,93,97)/t46-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63-,66+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.610n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50089441
PNG
(CHEMBL3578010)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C136H210N42O38/c1-65(2)50-90(168-128(212)100(63-180)175-110(194)70(11)156-118(202)94(55-73-25-33-78(183)34-26-73)170-123(207)95(56-74-27-35-79(184)36-28-74)169-113(197)83(19-14-46-152-134(144)145)159-125(209)98(59-103(139)187)173-120(204)91(51-66(3)4)165-117(201)87(40-43-105(189)190)161-116(200)88(41-44-106(191)192)162-129(213)101-22-17-49-178(101)132(216)81(137)62-179)119(203)158-84(20-15-47-153-135(146)147)114(198)172-97(58-76-61-150-64-155-76)124(208)171-96(57-75-29-37-80(185)38-30-75)122(206)166-92(52-67(5)6)121(205)174-99(60-104(140)188)126(210)167-93(53-68(7)8)127(211)176-107(69(9)10)130(214)177-108(71(12)181)131(215)163-85(21-16-48-154-136(148)149)111(195)160-86(39-42-102(138)186)115(199)157-82(18-13-45-151-133(142)143)112(196)164-89(109(141)193)54-72-23-31-77(182)32-24-72/h23-38,61,64-71,81-101,107-108,179-185H,13-22,39-60,62-63,137H2,1-12H3,(H2,138,186)(H2,139,187)(H2,140,188)(H2,141,193)(H,150,155)(H,156,202)(H,157,199)(H,158,203)(H,159,209)(H,160,195)(H,161,200)(H,162,213)(H,163,215)(H,164,196)(H,165,201)(H,166,206)(H,167,210)(H,168,212)(H,169,197)(H,170,207)(H,171,208)(H,172,198)(H,173,204)(H,174,205)(H,175,194)(H,176,211)(H,177,214)(H,189,190)(H,191,192)(H4,142,143,151)(H4,144,145,152)(H4,146,147,153)(H4,148,149,154)/t70-,71+,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,107-,108-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 0.631n/an/an/an/a



Universit£t Leipzig

Curated by ChEMBL


Assay Description
Agonist activity at human neuropeptide Y Y2 receptor expressed in COS-7 cells cotransfected with chimeric Gi/q protein assessed as inositol phosphate...


J Med Chem 58: 4180-93 (2015)


Article DOI: 10.1021/jm501702q
BindingDB Entry DOI: 10.7270/Q2P84DNK
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269177
PNG
(CHEMBL4101589)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(C)(C)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C79H136N28O19/c1-41(2)33-52(68(120)105-79(7,8)74(126)104-60(42(3)109)71(123)98-49(25-17-31-92-77(87)88)62(114)96-50(27-28-58(80)111)65(117)95-47(23-15-29-90-75(83)84)63(115)99-51(61(82)113)34-44-19-11-9-12-20-44)100-67(119)55(37-59(81)112)103-73(125)78(5,6)106-69(121)53(35-45-21-13-10-14-22-45)101-66(118)54(36-46-38-89-40-93-46)102-64(116)48(24-16-30-91-76(85)86)97-70(122)57-26-18-32-107(57)72(124)56(39-108)94-43(4)110/h38,40-42,44-45,47-57,60,108-109H,9-37,39H2,1-8H3,(H2,80,111)(H2,81,112)(H2,82,113)(H,89,93)(H,94,110)(H,95,117)(H,96,114)(H,97,122)(H,98,123)(H,99,115)(H,100,119)(H,101,118)(H,102,116)(H,103,125)(H,104,126)(H,105,120)(H,106,121)(H4,83,84,90)(H4,85,86,91)(H4,87,88,92)/t42-,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57-,60+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.660n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254309
PNG
(CHEMBL4061596)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](Cc1cnc[nH]1)C(=O)NC(CC1CCCCC1)C(=O)NC(CC1CCCCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O
Show InChI InChI=1/C86H151N29O19/c1-45(2)35-58(107-79(131)64(43-116)113-69(121)47(5)87)74(126)103-54(28-19-33-99-84(93)94)72(124)111-62(40-52-42-97-44-101-52)77(129)110-60(38-50-23-14-10-15-24-50)75(127)109-61(39-51-25-16-11-17-26-51)76(128)112-63(41-66(89)119)78(130)108-59(36-46(3)4)80(132)115-86(7,8)82(134)114-67(48(6)117)81(133)105-55(29-20-34-100-85(95)96)70(122)104-56(30-31-65(88)118)73(125)102-53(27-18-32-98-83(91)92)71(123)106-57(68(90)120)37-49-21-12-9-13-22-49/h42,44-51,53-64,67,116-117H,9-41,43,87H2,1-8H3,(H2,88,118)(H2,89,119)(H2,90,120)(H,97,101)(H,102,125)(H,103,126)(H,104,122)(H,105,133)(H,106,123)(H,107,131)(H,108,130)(H,109,127)(H,110,129)(H,111,124)(H,112,128)(H,113,121)(H,114,134)(H,115,132)(H4,91,92,98)(H4,93,94,99)(H4,95,96,100)/t47-,48+,53-,54-,55-,56-,57?,58-,59-,60?,61?,62+,63-,64-,67-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
KEGG
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.740n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269178
PNG
(CHEMBL4075287)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C83H137N29O19/c1-44(2)35-56(75(127)111-83(5,6)79(131)110-65(45(3)114)77(129)103-53(23-15-31-97-82(91)92)67(119)101-54(25-26-63(84)116)70(122)100-51(21-13-29-95-80(87)88)68(120)104-55(66(86)118)36-47-17-9-7-10-18-47)105-74(126)60(40-64(85)117)109-72(124)58(38-49-27-32-93-33-28-49)106-71(123)57(37-48-19-11-8-12-20-48)107-73(125)59(39-50-41-94-43-98-50)108-69(121)52(22-14-30-96-81(89)90)102-76(128)62-24-16-34-112(62)78(130)61(42-113)99-46(4)115/h27-28,32-33,41,43-45,47-48,51-62,65,113-114H,7-26,29-31,34-40,42H2,1-6H3,(H2,84,116)(H2,85,117)(H2,86,118)(H,94,98)(H,99,115)(H,100,122)(H,101,119)(H,102,128)(H,103,129)(H,104,120)(H,105,126)(H,106,123)(H,107,125)(H,108,121)(H,109,124)(H,110,131)(H,111,127)(H4,87,88,95)(H4,89,90,96)(H4,91,92,97)/t45-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62-,65+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 0.75n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254335
PNG
(CHEMBL4070864)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(CC1CCCCC1)NC(=O)C(CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CN(C)C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O
Show InChI InChI=1/C82H142N28O19/c1-44(2)34-56(75(126)109-82(5,6)78(129)108-65(45(3)112)76(127)101-53(28-19-33-95-81(90)91)68(119)100-54(29-30-62(83)114)70(121)99-52(27-18-32-94-80(88)89)69(120)102-55(66(85)117)35-47-20-11-8-12-21-47)103-74(125)60(39-63(84)115)107-72(123)58(37-49-24-15-10-16-25-49)104-71(122)57(36-48-22-13-9-14-23-48)105-73(124)59(38-50-40-92-43-96-50)106-67(118)51(26-17-31-93-79(86)87)98-64(116)41-110(7)77(128)61(42-111)97-46(4)113/h40,43-45,47-49,51-61,65,111-112H,8-39,41-42H2,1-7H3,(H2,83,114)(H2,84,115)(H2,85,117)(H,92,96)(H,97,113)(H,98,116)(H,99,121)(H,100,119)(H,101,127)(H,102,120)(H,103,125)(H,104,122)(H,105,124)(H,106,118)(H,107,123)(H,108,129)(H,109,126)(H4,86,87,93)(H4,88,89,94)(H4,90,91,95)/t45-,51+,52+,53+,54+,55?,56+,57?,58?,59+,60+,61+,65+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 1n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50444587
PNG
(CHEMBL3099724)
Show SMILES CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C177H273N53O54/c1-16-88(10)138(182)168(279)212-112(26-17-18-60-178)172(283)229-66-24-32-127(229)166(277)209-109(52-57-134(244)245)145(256)202-92(14)171(282)228-65-23-31-126(228)165(276)197-80-132(241)203-107(51-56-133(242)243)150(261)223-123(78-137(250)251)156(267)200-90(12)143(254)225-125(82-232)173(284)230-67-25-33-128(230)167(278)210-111(54-59-136(248)249)152(263)208-110(53-58-135(246)247)153(264)214-115(69-85(4)5)158(269)222-122(77-131(181)240)163(274)206-104(28-20-62-194-175(186)187)148(259)217-118(73-96-38-46-101(236)47-39-96)161(272)218-117(72-95-36-44-100(235)45-37-95)154(265)199-89(11)142(253)224-124(81-231)164(275)216-114(68-84(2)3)157(268)205-105(29-21-63-195-176(188)189)149(260)220-120(75-98-79-192-83-198-98)162(273)219-119(74-97-40-48-102(237)49-41-97)160(271)215-116(70-86(6)7)159(270)221-121(76-130(180)239)155(266)201-91(13)144(255)226-139(87(8)9)169(280)227-140(93(15)233)170(281)211-106(30-22-64-196-177(190)191)146(257)207-108(50-55-129(179)238)151(262)204-103(27-19-61-193-174(184)185)147(258)213-113(141(183)252)71-94-34-42-99(234)43-35-94/h34-49,79,83-93,103-128,138-140,231-237H,16-33,50-78,80-82,178,182H2,1-15H3,(H2,179,238)(H2,180,239)(H2,181,240)(H2,183,252)(H,192,198)(H,197,276)(H,199,265)(H,200,267)(H,201,266)(H,202,256)(H,203,241)(H,204,262)(H,205,268)(H,206,274)(H,207,257)(H,208,263)(H,209,277)(H,210,278)(H,211,281)(H,212,279)(H,213,258)(H,214,264)(H,215,271)(H,216,275)(H,217,259)(H,218,272)(H,219,273)(H,220,260)(H,221,270)(H,222,269)(H,223,261)(H,224,253)(H,225,254)(H,226,255)(H,227,280)(H,242,243)(H,244,245)(H,246,247)(H,248,249)(H,250,251)(H4,184,185,193)(H4,186,187,194)(H4,188,189,195)(H4,190,191,196)/t88-,89-,90-,91-,92-,93+,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,138-,139-,140-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/an/an/a 1n/an/an/an/a



University of Copenhagen

Curated by ChEMBL


Assay Description
Agonist activity at human NPYY2 receptor expressed in HEK293 cells assessed as decrease in isoproterenol-induced cAMP level measured every 30 secs fo...


ACS Med Chem Lett 4: 1228-32 (2013)


Article DOI: 10.1021/ml400335g
BindingDB Entry DOI: 10.7270/Q28S4RD1
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50197025
PNG
(CHEMBL439904 | PYY(3-36))
Show SMILES CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1S/C180H279N53O54/c1-17-91(12)141(185)171(282)214-114(27-18-19-61-181)175(286)232-67-25-33-130(232)169(280)211-111(53-58-137(247)248)147(258)204-94(15)174(285)231-66-24-32-129(231)168(279)200-82-135(244)205-109(52-57-136(245)246)152(263)226-126(80-140(253)254)157(268)203-93(14)146(257)228-128(84-235)176(287)233-68-26-34-131(233)170(281)212-113(55-60-139(251)252)154(265)210-112(54-59-138(249)250)155(266)216-117(70-87(4)5)159(270)224-124(78-133(183)242)164(275)208-106(29-21-63-197-178(189)190)150(261)220-121(75-98-39-47-103(239)48-40-98)162(273)221-120(74-97-37-45-102(238)46-38-97)156(267)202-92(13)145(256)227-127(83-234)167(278)219-116(69-86(2)3)158(269)207-107(30-22-64-198-179(191)192)151(262)223-123(77-100-81-195-85-201-100)163(274)222-122(76-99-41-49-104(240)50-42-99)161(272)217-118(71-88(6)7)160(271)225-125(79-134(184)243)165(276)218-119(72-89(8)9)166(277)229-142(90(10)11)172(283)230-143(95(16)236)173(284)213-108(31-23-65-199-180(193)194)148(259)209-110(51-56-132(182)241)153(264)206-105(28-20-62-196-177(187)188)149(260)215-115(144(186)255)73-96-35-43-101(237)44-36-96/h35-50,81,85-95,105-131,141-143,234-240H,17-34,51-80,82-84,181,185H2,1-16H3,(H2,182,241)(H2,183,242)(H2,184,243)(H2,186,255)(H,195,201)(H,200,279)(H,202,267)(H,203,268)(H,204,258)(H,205,244)(H,206,264)(H,207,269)(H,208,275)(H,209,259)(H,210,265)(H,211,280)(H,212,281)(H,213,284)(H,214,282)(H,215,260)(H,216,266)(H,217,272)(H,218,276)(H,219,278)(H,220,261)(H,221,273)(H,222,274)(H,223,262)(H,224,270)(H,225,271)(H,226,263)(H,227,256)(H,228,257)(H,229,277)(H,230,283)(H,245,246)(H,247,248)(H,249,250)(H,251,252)(H,253,254)(H4,187,188,196)(H4,189,190,197)(H4,191,192,198)(H4,193,194,199)/t91-,92-,93-,94-,95+,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,129-,130-,131-,141-,142-,143-/m0/s1
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 1n/an/an/an/a



University of Copenhagen

Curated by ChEMBL


Assay Description
Agonist activity at human NPYY2 receptor expressed in HEK293 cells assessed as decrease in isoproterenol-induced cAMP level measured every 30 secs fo...


ACS Med Chem Lett 4: 1228-32 (2013)


Article DOI: 10.1021/ml400335g
BindingDB Entry DOI: 10.7270/Q28S4RD1
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269179
PNG
(CHEMBL4103628)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C81H136N30O19/c1-42(2)31-54(73(126)110-81(5,6)77(130)109-63(43(3)113)75(128)102-51(23-15-29-95-80(89)90)65(118)100-52(25-26-61(82)115)68(121)99-49(21-13-27-93-78(85)86)66(119)103-53(64(84)117)32-45-17-9-7-10-18-45)104-72(125)58(36-62(83)116)108-71(124)57(35-48-38-92-41-97-48)107-69(122)55(33-46-19-11-8-12-20-46)105-70(123)56(34-47-37-91-40-96-47)106-67(120)50(22-14-28-94-79(87)88)101-74(127)60-24-16-30-111(60)76(129)59(39-112)98-44(4)114/h37-38,40-43,45-46,49-60,63,112-113H,7-36,39H2,1-6H3,(H2,82,115)(H2,83,116)(H2,84,117)(H,91,96)(H,92,97)(H,98,114)(H,99,121)(H,100,118)(H,101,127)(H,102,128)(H,103,119)(H,104,125)(H,105,123)(H,106,120)(H,107,122)(H,108,124)(H,109,130)(H,110,126)(H4,85,86,93)(H4,87,88,94)(H4,89,90,95)/t43-,49+,50+,51+,52+,53+,54+,55+,56+,57+,58+,59+,60-,63+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 1n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254306
PNG
(CHEMBL4081767)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(CC1CCCCC1)NC(=O)C(CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N(C)C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O
Show InChI InChI=1/C83H144N28O19/c1-44(2)35-57(76(127)110-83(6,7)79(130)109-65(46(4)113)77(128)102-54(29-20-34-96-82(91)92)68(119)101-55(30-31-63(84)115)71(122)100-53(28-19-33-95-81(89)90)69(120)103-56(66(86)117)36-48-21-12-9-13-22-48)104-75(126)61(40-64(85)116)108-73(124)59(38-50-25-16-11-17-26-50)105-72(123)58(37-49-23-14-10-15-24-49)106-74(125)60(39-51-41-93-43-97-51)107-70(121)52(27-18-32-94-80(87)88)99-67(118)45(3)111(8)78(129)62(42-112)98-47(5)114/h41,43-46,48-50,52-62,65,112-113H,9-40,42H2,1-8H3,(H2,84,115)(H2,85,116)(H2,86,117)(H,93,97)(H,98,114)(H,99,118)(H,100,122)(H,101,119)(H,102,128)(H,103,120)(H,104,126)(H,105,123)(H,106,125)(H,107,121)(H,108,124)(H,109,130)(H,110,127)(H4,87,88,94)(H4,89,90,95)(H4,91,92,96)/t45-,46+,52-,53-,54-,55-,56?,57-,58?,59?,60-,61-,62-,65-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 1.20n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50444587
PNG
(CHEMBL3099724)
Show SMILES CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C177H273N53O54/c1-16-88(10)138(182)168(279)212-112(26-17-18-60-178)172(283)229-66-24-32-127(229)166(277)209-109(52-57-134(244)245)145(256)202-92(14)171(282)228-65-23-31-126(228)165(276)197-80-132(241)203-107(51-56-133(242)243)150(261)223-123(78-137(250)251)156(267)200-90(12)143(254)225-125(82-232)173(284)230-67-25-33-128(230)167(278)210-111(54-59-136(248)249)152(263)208-110(53-58-135(246)247)153(264)214-115(69-85(4)5)158(269)222-122(77-131(181)240)163(274)206-104(28-20-62-194-175(186)187)148(259)217-118(73-96-38-46-101(236)47-39-96)161(272)218-117(72-95-36-44-100(235)45-37-95)154(265)199-89(11)142(253)224-124(81-231)164(275)216-114(68-84(2)3)157(268)205-105(29-21-63-195-176(188)189)149(260)220-120(75-98-79-192-83-198-98)162(273)219-119(74-97-40-48-102(237)49-41-97)160(271)215-116(70-86(6)7)159(270)221-121(76-130(180)239)155(266)201-91(13)144(255)226-139(87(8)9)169(280)227-140(93(15)233)170(281)211-106(30-22-64-196-177(190)191)146(257)207-108(50-55-129(179)238)151(262)204-103(27-19-61-193-174(184)185)147(258)213-113(141(183)252)71-94-34-42-99(234)43-35-94/h34-49,79,83-93,103-128,138-140,231-237H,16-33,50-78,80-82,178,182H2,1-15H3,(H2,179,238)(H2,180,239)(H2,181,240)(H2,183,252)(H,192,198)(H,197,276)(H,199,265)(H,200,267)(H,201,266)(H,202,256)(H,203,241)(H,204,262)(H,205,268)(H,206,274)(H,207,257)(H,208,263)(H,209,277)(H,210,278)(H,211,281)(H,212,279)(H,213,258)(H,214,264)(H,215,271)(H,216,275)(H,217,259)(H,218,272)(H,219,273)(H,220,260)(H,221,270)(H,222,269)(H,223,261)(H,224,253)(H,225,254)(H,226,255)(H,227,280)(H,242,243)(H,244,245)(H,246,247)(H,248,249)(H,250,251)(H4,184,185,193)(H4,186,187,194)(H4,188,189,195)(H4,190,191,196)/t88-,89-,90-,91-,92-,93+,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,138-,139-,140-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/an/an/a 1.30n/an/an/an/a



University of Copenhagen

Curated by ChEMBL


Assay Description
Agonist activity at human NPYY2 receptor expressed in HEK293 cells assessed as decrease in isoproterenol-induced cAMP level measured every 30 secs fo...


ACS Med Chem Lett 4: 1228-32 (2013)


Article DOI: 10.1021/ml400335g
BindingDB Entry DOI: 10.7270/Q28S4RD1
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254308
PNG
(CHEMBL4086266)
Show SMILES CCC(NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CO)NC(C)=O)C(=O)NC(CC1CCCCC1)C(=O)NC(CC1CCCCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O
Show InChI InChI=1/C83H148N26O19/c1-10-51(97-68(117)52(29-20-34-93-80(87)88)99-72(121)57(37-44(2)3)103-76(125)62(43-110)96-47(7)112)67(116)105-59(40-49-25-16-12-17-26-49)73(122)106-60(41-50-27-18-13-19-28-50)74(123)107-61(42-64(85)114)75(124)104-58(38-45(4)5)77(126)109-83(8,9)79(128)108-65(46(6)111)78(127)101-54(31-22-36-95-82(91)92)69(118)100-55(32-33-63(84)113)71(120)98-53(30-21-35-94-81(89)90)70(119)102-56(66(86)115)39-48-23-14-11-15-24-48/h44-46,48-62,65,110-111H,10-43H2,1-9H3,(H2,84,113)(H2,85,114)(H2,86,115)(H,96,112)(H,97,117)(H,98,120)(H,99,121)(H,100,118)(H,101,127)(H,102,119)(H,103,125)(H,104,124)(H,105,116)(H,106,122)(H,107,123)(H,108,128)(H,109,126)(H4,87,88,93)(H4,89,90,94)(H4,91,92,95)/t46-,51?,52+,53+,54+,55+,56?,57-,58+,59?,60?,61+,62+,65+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 1.30n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254360
PNG
(CHEMBL4073606)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(CC1CCCCC1)NC(=O)C(CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O
Show InChI InChI=1/C81H140N28O19/c1-43(2)33-55(75(126)109-81(5,6)77(128)108-64(44(3)111)76(127)101-52(27-18-32-94-80(89)90)68(119)100-53(28-29-61(82)113)70(121)99-51(26-17-31-93-79(87)88)69(120)102-54(65(84)116)34-46-19-10-7-11-20-46)103-74(125)59(38-62(83)114)107-72(123)57(36-48-23-14-9-15-24-48)104-71(122)56(35-47-21-12-8-13-22-47)105-73(124)58(37-49-39-91-42-96-49)106-67(118)50(25-16-30-92-78(85)86)98-63(115)40-95-66(117)60(41-110)97-45(4)112/h39,42-44,46-48,50-60,64,110-111H,7-38,40-41H2,1-6H3,(H2,82,113)(H2,83,114)(H2,84,116)(H,91,96)(H,95,117)(H,97,112)(H,98,115)(H,99,121)(H,100,119)(H,101,127)(H,102,120)(H,103,125)(H,104,122)(H,105,124)(H,106,118)(H,107,123)(H,108,128)(H,109,126)(H4,85,86,92)(H4,87,88,93)(H4,89,90,94)/t44-,50+,51+,52+,53+,54?,55+,56?,57?,58+,59+,60+,64+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 1.30n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50089436
PNG
(CHEMBL3578015)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CCCCNC(=O)CCNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](Cc1cccc2ccccc12)NC(=O)[C@@H](N)CCCCN)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C140H209N39O28/c1-75(2)60-102(169-121(191)95(161-81(12)181)37-21-23-55-154-116(187)53-59-155-120(190)99(49-51-113(143)184)164-127(197)103(61-76(3)4)171-133(203)110(69-87-72-159-94-36-19-18-34-92(87)94)176-131(201)107(66-82-28-14-13-15-29-82)174-132(202)109(168-119(189)93(142)35-20-22-54-141)68-86-32-24-31-85-30-16-17-33-91(85)86)126(196)163-97(39-26-57-157-139(149)150)124(194)177-111(70-88-73-153-74-160-88)134(204)175-108(67-84-43-47-90(183)48-44-84)130(200)170-105(63-78(7)8)129(199)178-112(71-115(145)186)135(205)172-104(62-77(5)6)128(198)173-106(64-79(9)10)136(206)179-117(80(11)180)137(207)166-98(40-27-58-158-140(151)152)122(192)165-100(50-52-114(144)185)125(195)162-96(38-25-56-156-138(147)148)123(193)167-101(118(146)188)65-83-41-45-89(182)46-42-83/h13-19,24,28-34,36,41-48,72-80,93,95-112,117,159,180,182-183H,20-23,25-27,35,37-40,49-71,141-142H2,1-12H3,(H2,143,184)(H2,144,185)(H2,145,186)(H2,146,188)(H,153,160)(H,154,187)(H,155,190)(H,161,181)(H,162,195)(H,163,196)(H,164,197)(H,165,192)(H,166,207)(H,167,193)(H,168,189)(H,169,191)(H,170,200)(H,171,203)(H,172,205)(H,173,198)(H,174,202)(H,175,204)(H,176,201)(H,177,194)(H,178,199)(H,179,206)(H4,147,148,156)(H4,149,150,157)(H4,151,152,158)/t80-,93+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109-,110-,111+,112+,117+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 1.60n/an/an/an/a



Universit£t Leipzig

Curated by ChEMBL


Assay Description
Agonist activity at human neuropeptide Y Y2 receptor expressed in COS-7 cells cotransfected with chimeric Gi/q protein assessed as inositol phosphate...


J Med Chem 58: 4180-93 (2015)


Article DOI: 10.1021/jm501702q
BindingDB Entry DOI: 10.7270/Q2P84DNK
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50089436
PNG
(CHEMBL3578015)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CCCCNC(=O)CCNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](Cc1cccc2ccccc12)NC(=O)[C@@H](N)CCCCN)NC(C)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C140H209N39O28/c1-75(2)60-102(169-121(191)95(161-81(12)181)37-21-23-55-154-116(187)53-59-155-120(190)99(49-51-113(143)184)164-127(197)103(61-76(3)4)171-133(203)110(69-87-72-159-94-36-19-18-34-92(87)94)176-131(201)107(66-82-28-14-13-15-29-82)174-132(202)109(168-119(189)93(142)35-20-22-54-141)68-86-32-24-31-85-30-16-17-33-91(85)86)126(196)163-97(39-26-57-157-139(149)150)124(194)177-111(70-88-73-153-74-160-88)134(204)175-108(67-84-43-47-90(183)48-44-84)130(200)170-105(63-78(7)8)129(199)178-112(71-115(145)186)135(205)172-104(62-77(5)6)128(198)173-106(64-79(9)10)136(206)179-117(80(11)180)137(207)166-98(40-27-58-158-140(151)152)122(192)165-100(50-52-114(144)185)125(195)162-96(38-25-56-156-138(147)148)123(193)167-101(118(146)188)65-83-41-45-89(182)46-42-83/h13-19,24,28-34,36,41-48,72-80,93,95-112,117,159,180,182-183H,20-23,25-27,35,37-40,49-71,141-142H2,1-12H3,(H2,143,184)(H2,144,185)(H2,145,186)(H2,146,188)(H,153,160)(H,154,187)(H,155,190)(H,161,181)(H,162,195)(H,163,196)(H,164,197)(H,165,192)(H,166,207)(H,167,193)(H,168,189)(H,169,191)(H,170,200)(H,171,203)(H,172,205)(H,173,198)(H,174,202)(H,175,204)(H,176,201)(H,177,194)(H,178,199)(H,179,206)(H4,147,148,156)(H4,149,150,157)(H4,151,152,158)/t80-,93+,95+,96+,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109-,110-,111+,112+,117+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 1.70n/an/an/an/a



Universit£t Leipzig

Curated by ChEMBL


Assay Description
Agonist activity at human neuropeptide Y Y2 receptor expressed in COS-7 cells cotransfected with chimeric Gi/q protein assessed as inositol phosphate...


J Med Chem 58: 4180-93 (2015)


Article DOI: 10.1021/jm501702q
BindingDB Entry DOI: 10.7270/Q2P84DNK
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269175
PNG
(CHEMBL4064467)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)C(C)(C)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C79H136N28O19/c1-41(2)33-52(68(120)105-79(7,8)74(126)104-60(42(3)109)71(123)98-49(25-17-31-92-77(87)88)62(114)96-50(27-28-58(80)111)65(117)95-47(23-15-29-90-75(83)84)63(115)99-51(61(82)113)34-44-19-11-9-12-20-44)100-67(119)55(37-59(81)112)102-66(118)53(35-45-21-13-10-14-22-45)103-73(125)78(5,6)106-69(121)54(36-46-38-89-40-93-46)101-64(116)48(24-16-30-91-76(85)86)97-70(122)57-26-18-32-107(57)72(124)56(39-108)94-43(4)110/h38,40-42,44-45,47-57,60,108-109H,9-37,39H2,1-8H3,(H2,80,111)(H2,81,112)(H2,82,113)(H,89,93)(H,94,110)(H,95,117)(H,96,114)(H,97,122)(H,98,123)(H,99,115)(H,100,119)(H,101,116)(H,102,118)(H,103,125)(H,104,126)(H,105,120)(H,106,121)(H4,83,84,90)(H4,85,86,91)(H4,87,88,92)/t42-,47+,48+,49+,50+,51+,52+,53+,54+,55+,56+,57-,60+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem
PubMed
n/an/an/an/a 1.70n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269172
PNG
(CHEMBL4065752)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccncc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C83H137N29O19/c1-44(2)35-56(75(127)111-83(5,6)79(131)110-65(45(3)114)77(129)103-53(23-15-31-97-82(91)92)67(119)101-54(25-26-63(84)116)70(122)100-51(21-13-29-95-80(87)88)68(120)104-55(66(86)118)36-47-17-9-7-10-18-47)105-74(126)60(40-64(85)117)109-72(124)57(37-48-19-11-8-12-20-48)106-71(123)58(38-49-27-32-93-33-28-49)107-73(125)59(39-50-41-94-43-98-50)108-69(121)52(22-14-30-96-81(89)90)102-76(128)62-24-16-34-112(62)78(130)61(42-113)99-46(4)115/h27-28,32-33,41,43-45,47-48,51-62,65,113-114H,7-26,29-31,34-40,42H2,1-6H3,(H2,84,116)(H2,85,117)(H2,86,118)(H,94,98)(H,99,115)(H,100,122)(H,101,119)(H,102,128)(H,103,129)(H,104,120)(H,105,126)(H,106,123)(H,107,125)(H,108,121)(H,109,124)(H,110,131)(H,111,127)(H4,87,88,95)(H4,89,90,96)(H4,91,92,97)/t45-,51+,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62-,65+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 1.80n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50089440
PNG
(CHEMBL3578018)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cccc2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CCC(=O)NCC(NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)C(N)=O
Show InChI InChI=1/C145H218N40O29/c1-77(2)60-103(122(150)194)172-131(203)106(62-79(5)6)175-137(209)113(70-90-73-162-96-37-21-20-36-95(90)96)182-135(207)110(67-85-30-16-15-17-31-85)179-136(208)112(69-89-34-26-33-88-32-18-19-35-94(88)89)181-127(199)98(39-23-25-56-147)167-124(196)97(38-22-24-55-146)166-120(193)54-53-119(192)163-75-116(165-84(14)187)141(213)178-105(61-78(3)4)130(202)169-100(41-28-58-160-144(154)155)128(200)183-114(71-91-74-158-76-164-91)138(210)180-111(68-87-45-49-93(189)50-46-87)134(206)174-108(64-81(9)10)133(205)184-115(72-118(149)191)139(211)176-107(63-80(7)8)132(204)177-109(65-82(11)12)140(212)185-121(83(13)186)142(214)171-101(42-29-59-161-145(156)157)125(197)170-102(51-52-117(148)190)129(201)168-99(40-27-57-159-143(152)153)126(198)173-104(123(151)195)66-86-43-47-92(188)48-44-86/h15-21,26,30-37,43-50,73-74,76-83,97-116,121,162,186,188-189H,22-25,27-29,38-42,51-72,75,146-147H2,1-14H3,(H2,148,190)(H2,149,191)(H2,150,194)(H2,151,195)(H,158,164)(H,163,192)(H,165,187)(H,166,193)(H,167,196)(H,168,201)(H,169,202)(H,170,197)(H,171,214)(H,172,203)(H,173,198)(H,174,206)(H,175,209)(H,176,211)(H,177,204)(H,178,213)(H,179,208)(H,180,210)(H,181,199)(H,182,207)(H,183,200)(H,184,205)(H,185,212)(H4,152,153,159)(H4,154,155,160)(H4,156,157,161)/t83-,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113-,114+,115+,116?,121+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 2n/an/an/an/a



Universit£t Leipzig

Curated by ChEMBL


Assay Description
Agonist activity at human neuropeptide Y Y2 receptor expressed in COS-7 cells cotransfected with chimeric Gi/q protein assessed as inositol phosphate...


J Med Chem 58: 4180-93 (2015)


Article DOI: 10.1021/jm501702q
BindingDB Entry DOI: 10.7270/Q2P84DNK
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269164
PNG
(CHEMBL4071371)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)c1ccccc1)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C81H134N26O16/c1-45(2)37-57(75(121)107-81(4,5)77(123)106-64(46(3)108)76(122)99-54(31-20-36-94-80(89)90)67(113)98-55(32-33-62(82)109)70(116)97-53(30-19-35-93-79(87)88)68(114)100-56(65(84)111)38-47-21-10-6-11-22-47)101-74(120)61(42-63(83)110)105-72(118)59(40-49-25-14-8-15-26-49)102-71(117)58(39-48-23-12-7-13-24-48)103-73(119)60(41-51-43-91-44-95-51)104-69(115)52(29-18-34-92-78(85)86)96-66(112)50-27-16-9-17-28-50/h9,16-17,27-28,43-49,52-61,64,108H,6-8,10-15,18-26,29-42H2,1-5H3,(H2,82,109)(H2,83,110)(H2,84,111)(H,91,95)(H,96,112)(H,97,116)(H,98,113)(H,99,122)(H,100,114)(H,101,120)(H,102,117)(H,103,119)(H,104,115)(H,105,118)(H,106,123)(H,107,121)(H4,85,86,92)(H4,87,88,93)(H4,89,90,94)/t46-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,64+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 2n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254334
PNG
(CHEMBL4097131)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)C(CC1CCCCC1)NC(=O)C(CC1CCCCC1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)c1ccccc1)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O
Show InChI InChI=1/C81H134N26O16/c1-45(2)37-57(75(121)107-81(4,5)77(123)106-64(46(3)108)76(122)99-54(31-20-36-94-80(89)90)67(113)98-55(32-33-62(82)109)70(116)97-53(30-19-35-93-79(87)88)68(114)100-56(65(84)111)38-47-21-10-6-11-22-47)101-74(120)61(42-63(83)110)105-72(118)59(40-49-25-14-8-15-26-49)102-71(117)58(39-48-23-12-7-13-24-48)103-73(119)60(41-51-43-91-44-95-51)104-69(115)52(29-18-34-92-78(85)86)96-66(112)50-27-16-9-17-28-50/h9,16-17,27-28,43-49,52-61,64,108H,6-8,10-15,18-26,29-42H2,1-5H3,(H2,82,109)(H2,83,110)(H2,84,111)(H,91,95)(H,96,112)(H,97,116)(H,98,113)(H,99,122)(H,100,114)(H,101,120)(H,102,117)(H,103,119)(H,104,115)(H,105,118)(H,106,123)(H,107,121)(H4,85,86,92)(H4,87,88,93)(H4,89,90,94)/t46-,52+,53+,54+,55+,56?,57+,58?,59?,60+,61+,64+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 2n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50089440
PNG
(CHEMBL3578018)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1cccc2ccccc12)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)CCC(=O)NCC(NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O)C(N)=O
Show InChI InChI=1/C145H218N40O29/c1-77(2)60-103(122(150)194)172-131(203)106(62-79(5)6)175-137(209)113(70-90-73-162-96-37-21-20-36-95(90)96)182-135(207)110(67-85-30-16-15-17-31-85)179-136(208)112(69-89-34-26-33-88-32-18-19-35-94(88)89)181-127(199)98(39-23-25-56-147)167-124(196)97(38-22-24-55-146)166-120(193)54-53-119(192)163-75-116(165-84(14)187)141(213)178-105(61-78(3)4)130(202)169-100(41-28-58-160-144(154)155)128(200)183-114(71-91-74-158-76-164-91)138(210)180-111(68-87-45-49-93(189)50-46-87)134(206)174-108(64-81(9)10)133(205)184-115(72-118(149)191)139(211)176-107(63-80(7)8)132(204)177-109(65-82(11)12)140(212)185-121(83(13)186)142(214)171-101(42-29-59-161-145(156)157)125(197)170-102(51-52-117(148)190)129(201)168-99(40-27-57-159-143(152)153)126(198)173-104(123(151)195)66-86-43-47-92(188)48-44-86/h15-21,26,30-37,43-50,73-74,76-83,97-116,121,162,186,188-189H,22-25,27-29,38-42,51-72,75,146-147H2,1-14H3,(H2,148,190)(H2,149,191)(H2,150,194)(H2,151,195)(H,158,164)(H,163,192)(H,165,187)(H,166,193)(H,167,196)(H,168,201)(H,169,202)(H,170,197)(H,171,214)(H,172,203)(H,173,198)(H,174,206)(H,175,209)(H,176,211)(H,177,204)(H,178,213)(H,179,208)(H,180,210)(H,181,199)(H,182,207)(H,183,200)(H,184,205)(H,185,212)(H4,152,153,159)(H4,154,155,160)(H4,156,157,161)/t83-,97+,98+,99+,100+,101+,102+,103+,104+,105+,106+,107+,108+,109+,110+,111+,112+,113-,114+,115+,116?,121+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem

Similars

Article
PubMed
n/an/an/an/a 2n/an/an/an/a



Universit£t Leipzig

Curated by ChEMBL


Assay Description
Agonist activity at human neuropeptide Y Y2 receptor expressed in COS-7 cells cotransfected with chimeric Gi/q protein assessed as inositol phosphate...


J Med Chem 58: 4180-93 (2015)


Article DOI: 10.1021/jm501702q
BindingDB Entry DOI: 10.7270/Q2P84DNK
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50444588
PNG
(CHEMBL3099722)
Show SMILES CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)O[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(N)=O
Show InChI InChI=1/C177H272N52O55/c1-16-88(10)138(182)167(277)210-110(26-17-18-60-178)171(281)228-66-24-31-126(228)164(274)207-107(52-57-134(243)244)145(255)202-92(14)170(280)227-65-23-30-125(227)163(273)197-80-132(240)203-106(51-56-133(241)242)149(259)222-122(78-137(249)250)154(264)200-90(12)143(253)224-124(82-231)172(282)229-67-25-32-127(229)165(275)208-109(54-59-136(247)248)150(260)206-108(53-58-135(245)246)151(261)213-114(69-85(4)5)156(266)221-121(77-131(181)239)161(271)205-103(27-19-61-193-174(184)185)147(257)216-117(73-96-38-46-101(235)47-39-96)159(269)217-116(72-95-36-44-100(234)45-37-95)152(262)199-89(11)142(252)223-123(81-230)162(272)215-113(68-84(2)3)155(265)204-104(28-20-62-194-175(186)187)148(258)219-119(75-98-79-192-83-198-98)160(270)218-118(74-97-40-48-102(236)49-41-97)158(268)214-115(70-86(6)7)157(267)220-120(76-130(180)238)153(263)201-91(13)144(254)225-139(87(8)9)168(278)226-140(93(15)232)169(279)209-105(29-21-63-195-176(188)189)146(256)211-111(50-55-129(179)237)173(283)284-128(33-22-64-196-177(190)191)166(276)212-112(141(183)251)71-94-34-42-99(233)43-35-94/h34-49,79,83-93,103-128,138-140,230-236H,16-33,50-78,80-82,178,182H2,1-15H3,(H2,179,237)(H2,180,238)(H2,181,239)(H2,183,251)(H,192,198)(H,197,273)(H,199,262)(H,200,264)(H,201,263)(H,202,255)(H,203,240)(H,204,265)(H,205,271)(H,206,260)(H,207,274)(H,208,275)(H,209,279)(H,210,277)(H,211,256)(H,212,276)(H,213,261)(H,214,268)(H,215,272)(H,216,257)(H,217,269)(H,218,270)(H,219,258)(H,220,267)(H,221,266)(H,222,259)(H,223,252)(H,224,253)(H,225,254)(H,226,278)(H,241,242)(H,243,244)(H,245,246)(H,247,248)(H,249,250)(H4,184,185,193)(H4,186,187,194)(H4,188,189,195)(H4,190,191,196)/t88-,89-,90-,91-,92-,93+,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,127-,128-,138-,139-,140-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
CHEMBL
PC cid
PC sid
UniChem
Article
PubMed
n/an/an/an/a 2.20n/an/an/an/a



University of Copenhagen

Curated by ChEMBL


Assay Description
Agonist activity at human NPYY2 receptor expressed in HEK293 cells assessed as decrease in isoproterenol-induced cAMP level measured every 30 secs fo...


ACS Med Chem Lett 4: 1228-32 (2013)


Article DOI: 10.1021/ml400335g
BindingDB Entry DOI: 10.7270/Q28S4RD1
More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50254358
PNG
(CHEMBL4090636)
Show SMILES CCC(NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)C(=O)NC(CC1CCCCC1)C(=O)NC(CC1CCCCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC(CC1CCCCC1)C(N)=O
Show InChI InChI=1/C84H151N27O19/c1-10-51(98-69(119)52(29-20-34-95-81(89)90)100-73(123)57(37-44(2)3)104-77(127)62(43-112)109-67(117)46(6)85)68(118)106-59(40-49-25-16-12-17-26-49)74(124)107-60(41-50-27-18-13-19-28-50)75(125)108-61(42-64(87)115)76(126)105-58(38-45(4)5)78(128)111-84(8,9)80(130)110-65(47(7)113)79(129)102-54(31-22-36-97-83(93)94)70(120)101-55(32-33-63(86)114)72(122)99-53(30-21-35-96-82(91)92)71(121)103-56(66(88)116)39-48-23-14-11-15-24-48/h44-62,65,112-113H,10-43,85H2,1-9H3,(H2,86,114)(H2,87,115)(H2,88,116)(H,98,119)(H,99,122)(H,100,123)(H,101,120)(H,102,129)(H,103,121)(H,104,127)(H,105,126)(H,106,118)(H,107,124)(H,108,125)(H,109,117)(H,110,130)(H,111,128)(H4,89,90,95)(H4,91,92,96)(H4,93,94,97)/t46-,47+,51?,52-,53-,54-,55-,56?,57-,58-,59?,60?,61-,62-,65-/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
KEGG
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 2.5n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2R expressed in CHO cell membranes assessed as [35S]GTPgammaS binding after 120 mins by liquid scintillation method


ACS Med Chem Lett 8: 628-631 (2017)

More data for this
Ligand-Target Pair
Neuropeptide Y receptor type 2


(Homo sapiens (Human))
BDBM50269174
PNG
(CHEMBL4059729)
Show SMILES CC(C)C[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1CCCN1C(=O)[C@H](CO)NC(C)=O)C(=O)NC(C)(C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1CCCCC1)C(N)=O
Show InChI InChI=1/C84H138N28O20/c1-44(2)35-57(76(128)111-84(5,6)80(132)110-66(45(3)114)78(130)103-54(23-15-33-97-83(92)93)68(120)101-55(29-30-64(85)117)71(123)100-52(21-13-31-95-81(88)89)69(121)104-56(67(87)119)36-47-17-9-7-10-18-47)105-75(127)61(40-65(86)118)109-73(125)58(37-48-19-11-8-12-20-48)106-72(124)59(38-49-25-27-51(116)28-26-49)107-74(126)60(39-50-41-94-43-98-50)108-70(122)53(22-14-32-96-82(90)91)102-77(129)63-24-16-34-112(63)79(131)62(42-113)99-46(4)115/h25-28,41,43-45,47-48,52-63,66,113-114,116H,7-24,29-40,42H2,1-6H3,(H2,85,117)(H2,86,118)(H2,87,119)(H,94,98)(H,99,115)(H,100,123)(H,101,120)(H,102,129)(H,103,130)(H,104,121)(H,105,127)(H,106,124)(H,107,126)(H,108,122)(H,109,125)(H,110,132)(H,111,128)(H4,88,89,95)(H4,90,91,96)(H4,92,93,97)/t45-,52+,53+,54+,55+,56+,57+,58+,59+,60+,61+,62+,63-,66+/s2
Reactome pathway
KEGG

UniProtKB/SwissProt

DrugBank
GoogleScholar
PC cid
PC sid
UniChem

Similars

PubMed
n/an/an/an/a 2.5n/an/an/an/a



Takeda Pharmaceutical Co., Ltd

Curated by ChEMBL


Assay Description
Agonist activity at human Y2 receptor expressed in CHO cell membranes after 120 mins by [35S]GTPgammaS binding assay


Bioorg Med Chem Lett 27: 3829-3832 (2017)

More data for this
Ligand-Target Pair
Displayed 1 to 50 (of 1133 total )  |  Next  |  Last  >>
Jump to: